OptiNose, Inc. (OPTN): Price and Financial Metrics


OptiNose, Inc. (OPTN)

Today's Latest Price: $9.66 USD

0.41 (4.43%)

Updated Nov 13 12:00am

Add OPTN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

OPTN Stock Summary

  • OptiNose Inc's stock had its IPO on October 13, 2017, making it an older stock than only 5.53% of US equities in our set.
  • With a price/sales ratio of 24.64, OptiNose Inc has a higher such ratio than 95.62% of stocks in our set.
  • As for revenue growth, note that OPTN's revenue has grown 651.66% over the past 12 months; that beats the revenue growth of 98.96% of US companies in our set.
  • Stocks that are quantitatively similar to OPTN, based on their financial statements, market capitalization, and price volatility, are JT, RENN, GRVY, TEUM, and LAIX.
  • OPTN's SEC filings can be seen here. And to visit OptiNose Inc's official web site, go to www.optinose.com.
OPTN Daily Price Range
OPTN 52-Week Price Range

OPTN Stock Price Chart More Charts


OPTN Price/Volume Stats

Current price $9.66
Prev. close $9.25
Day low $9.08
Day high $10.55
50-day MA $7.68
200-day MA $7.82
52-week high $11.23
52-week low $4.44
Volume 416,900
Avg. volume 192,236
Dividend yield N/A
Market Cap 400.27M

OptiNose, Inc. (OPTN) Company Bio


OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.





OPTN Latest News Stream


Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream


Loading social stream, please wait...

View Full OPTN Social Stream

OPTN Price Returns

1-mo 36.63%
3-mo 52.13%
6-mo 5.34%
1-year -6.12%
3-year N/A
5-year N/A
YTD 55.81%
2018 -67.20%
2017 N/A
2016 N/A
2015 N/A
2014 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.4718 seconds.